[血管内皮生长因子、白细胞介素-17、β2微球蛋白及白细胞介素-35在多发性骨髓瘤患者中的表达水平及临床意义]
[Expression Level and Clinical Significance of VEGF, IL-17, β2-MG and IL-35 in Patients with Multiple Myeloma].
作者信息
Jin Xiao-Na, Zhou Bao-Zhen, Zhang Dang-Feng
机构信息
Xi' an International University of Medicine, Xi' an 710077, Shaanxi Province,China.
Department of Orthopedics, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an 710061, Shaanxi Province, China. E-mail:
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Feb;26(1):192-196. doi: 10.7534/j.issn.1009-2137.2018.01.033.
OBJECTIVE
To explore the expression and clinical significance of VEGF, IL-17, β2-MG and IL-35 in patients with multiple myeloma.
METHODS
A total of 83 patients with multiple myeloma (MM) from January 2012 to December 2016 were enrolled in MM group, 36 healthy subjects were enrolled in control group. The levels of IL-17, IL-35 and VEGF in serum were detected by ELISA. The levels of β2-MG in serum were measured by radioimmunoassay. The differences of different indexes between 2 groups were compared.
RESULTS
The serum levels of IL-17, VEGF and β2-MG in serum of III stage were higher than that in II stage, which was higher than that in I stage and control group (P<0.05). The levels of IL-35 in the control group were significantly higher than those in the I,II,III stage group (P<0.05). The levels of IL-17, VEGF and β2-MG in serum of progress period were higher than those in stable phase and control group, level of IL-35 in serum of control group was significantly higher than that in the stable phase and progress period group (P<0.05). The correlation analysis showed that the level of serum IL-17 positively correlated with VEGF, β2-MG expression (r=0.65, 0.58, P<0.05); and the serum IL-17 levels were negatively correlated with IL-35 levels (r=-0.42, P<0.05).
CONCLUSION
The anomalous levels of IL-17, IL-35, IVEGF and β2-MG expressions correlate with the progression and prognosis of patients with multiple myeloma.
目的
探讨血管内皮生长因子（VEGF）、白细胞介素-17（IL-17）、β2-微球蛋白（β2-MG）及白细胞介素-35（IL-35）在多发性骨髓瘤患者中的表达及临床意义。
方法
选取2012年1月至2016年12月期间收治的83例多发性骨髓瘤（MM）患者作为MM组，选取36例健康体检者作为对照组。采用酶联免疫吸附测定法（ELISA）检测血清中IL-17、IL-35及VEGF水平，采用放射免疫法测定血清中β2-MG水平。比较两组不同指标的差异。
结果
Ⅲ期患者血清IL-17、VEGF及β2-MG水平高于Ⅱ期，Ⅱ期高于Ⅰ期及对照组（P<0.05）。对照组IL-35水平显著高于Ⅰ、Ⅱ、Ⅲ期组（P<0.05）。进展期患者血清IL-17、VEGF及β2-MG水平高于稳定期及对照组，对照组血清IL-35水平显著高于稳定期及进展期组（P<0.05）。相关性分析显示，血清IL-17水平与VEGF、β2-MG表达呈正相关（r=0.65、0.58，P<0.05）；血清IL-17水平与IL-35水平呈负相关（r=-0.42，P<0.05）。
结论
IL-17、IL-35、VEGF及β2-MG表达异常与多发性骨髓瘤患者的病情进展及预后相关。
Zotero 插件